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Introduction: At the prior data cutoff (February 9, 2017)
the ALEX trial showed superior investigator-assessed
progression-free survival (PFS) for alectinib versus
crizotinib in untreated, anaplastic lymphoma kinase
(ALK)-positive, advanced NSCLC (hazard ratio ¼ 0.47,
95% conﬁdence interval: 0.34–0.65, p < 0.001). The
median PFS in the alectinib arm was not reached versus
11.1 months with crizotinib. Retrospective analyses sug-
gest that the echinoderm microtubule-associated protein-
like 4 gene-ALK variant (EML4-ALK) may inﬂuence
ALK-inhibitor treatment beneﬁt. We present updated
analyses, including exploratory subgroup analysis by
EML4-ALK variant, after an additional 10 months’ follow-
up (cutoff December 1, 2017).
Methods: Patients were randomized to receive twice-daily
alectinib, 600 mg, or crizotinib, 250 mg, until disease
progression, toxicity, death, or withdrawal. PFS was
determined by the investigators. Baseline plasma and
tissue biomarker samples were analyzed by using hybrid-
capture, next-generation sequencing to determine EML4-
ALK variant.
Results: Baseline characteristics were balanced. Investigator-
assessed PFS was prolonged with alectinib (stratiﬁed
hazard ratio ¼ 0.43, 95% conﬁdence interval: 0.32–0.58).
The median PFS times were 34.8 months with alectinib
and 10.9 months with crizotinib. EML4-ALK fusions were
detectable in 129 patient plasma samples and 124 tissue
samples; variants 1, 2, and 3/ab did not affect PFS, objective
response rate, or duration of response. Investigator-assessed
PFS was longer for alectinib than for crizotinib across
EML4-ALK variants 1, 2, and 3a/b in plasma and tissue.
Despite longer treatment duration (27.0 months in the case
of alectinib versus 10.8 months in the case of crizotinib),
the safety of alectinib compared favorably with that of
crizotinib.
Conclusion: Alectinib continues to demonstrate superior
investigator-assessed PFS versus crizotinib in untreated
ALK-positive NSCLC, irrespective of EML4-ALK variant.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Alectinib; Non–small cell lung cancer; ALEX;
EML4-ALK; NGSIntroduction
Alectinib is a highly selective and potent inhibitor of
anaplastic lymphoma kinase (ALK) that has demonstrated
good activity in patients with anaplastic lymphoma kinase
gene (ALK)-positive NSCLC who have progressed while
taking crizotinib or are intolerant to it.1,2 The phase III,
global, randomized ALEX trial (BO28984; NCT02075840)
demonstrated superior efﬁcacy and safety of alectinib
compared with crizotinib in patients with treatment-naive
ALK-positive NSCLC.3 The trial met its primary end point:
at the primary analysis (data cutoff February 9, 2017),
investigator-assessed progression-free survival (PFS) was
improved with alectinib versus with crizotinib in patients
with treatment-naive ALK-positive NSCLC.3 In the intent-to-
treat (ITT) population, the hazard ratio (HR) for disease
progression or death was 0.47 (95% conﬁdence interval
[CI]: 0.34–0.65,p<0.001),with themedianPFS for alectinib
not reached after a median follow-up of 18.6 months.3
ALK-positive disease is characterized by the presence
of an oncogene rearrangement leading to a structural
alteration of the chromosome and expression of consti-
tutively active ALK fusion proteins.4–6 The most common
ALK fusion partner is the echinoderm microtubule-
associated protein-like 4 gene (EML4); both are located
on the short arm of chromosome 2.5 The breakpoint of
the ALK gene occurs at exon 20, whereas the EML4
breakpoint differs to generate fusion protein variants.5–7
More than 15 EML4-ALK fusion variants have been
identiﬁed; the most common variants are 1 (EML4
breakpoint exon 13 [in 43% of cases]), 2 (EML4 break-
point exon 20 [in 6% of cases]) and 3a/b (EML4
breakpoint exon 6a/b [in 40% of cases]).5,8
Retrospective analyses have suggested that the
expression of particular EML4-ALK variants may inﬂu-
ence the degree of beneﬁt experienced by patients with
ALK-positive NSCLC in response to ALK inhibitors,
potentially by inﬂuencing the propensity to develop
speciﬁc secondary ALK resistance mutations. In one
study, ﬁrst-line crizotinib-treated patients with variant 1
were reported to have longer PFS than those with other
EML4-ALK variants,9 whereas patients with EML4-ALK
variant 3 treated with lorlatinib in a second- or later-
line setting were reported to have signiﬁcantly longer
PFS than those with variant 1.8 However, the available
evidence is limited; there is a lack of randomized clinical
trial data on the impact of EML4-ALK variants on treat-
ment efﬁcacy with ALK inhibitors, including alectinib.3,8
July 2019 Alectinib in NSCLC: Updated ALEX Study Data 1235Here we report updated efﬁcacy and safety data
from the ALEX study, with a further follow-up of
approximately 10 months (data cutoff December 1,
2017) and an exploratory analysis of efﬁcacy by EML4-
ALK fusion variant. We discuss the impact of fusion
variant type on beneﬁt from the ALK inhibitors alecti-
nib and crizotinib.
Methods
Study Design
Full details of the ALEX study design have been
previously published.3 Brieﬂy, 303 patients aged 18 years
or older with stage III or IV ALK-positive NSCLC were
randomized 1:1 to receive twice-daily alectinib, 600 mg,
or crizotinib, 250 mg, until progressive disease (PD),
toxicity, withdrawal, or death. Patients with asymptom-
atic brain metastases were permitted. Eligible patients
had histologically or cytologically diagnosed advanced
ALK-positive NSCLC, centrally tested by the VENTANA
ALK (D5F3) immunohistochemistry assay (Ventana
Medical Systems). Patients had no prior systemic treat-
ment for advanced NSCLC and an Eastern Cooperative
Oncology Group performance status of 0 to 2. Plasma and
tumor tissue samples were collected at baseline, and
biomarker-evaluable population (BEP) subgroups were
assessed. BEP subgroups consisted of those patients
with evaluable plasma or tissue samples (sufﬁcient
tumor tissue and/or circulating tumor DNA yield) that
passed next-generation sequencing (NGS) quality control.
The study protocol was approved by the institutional
review board or ethics committee at each participating
center, and the study was conducted in accordance with
the principles of the Declaration of Helsinki, Good Clin-
ical Practice Guidelines, and local laws. Written and
informed consent was obtained from all patients before
enrollment.
Study End Points
The primary end point of ALEX was investigator-
assessed PFS. Secondary end points included
independent review committee (IRC)-assessed PFS,
objective response rate (ORR), time to central nervous
system (CNS) progression, duration of response (DOR),
overall survival (OS), and safety. IRC-assessed end points
were evaluated only for the primary analysis and were
not planned for further analysis at later time points,
including this data cutoff (December 1, 2017).
Study Assessment
As reported by Peters et al. in 2017,3 brain imaging
was performed in all patients at baseline and every 8
weeks until PD. Response was assessed according to the
Response Evaluation Criteria in Solid Tumors (RECIST)version 1.1. Adverse events (AEs) were graded according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.0, and were clas-
siﬁed according to the Medical Dictionary for Regulatory
Activities. PFS and ORR, assessed by the investigator,
were determined in each of the BEP subgroups and for
each of the EML4-ALK fusion variant populations
(updated data cutoff December 1, 2017). PFS was
deﬁned as the time from randomization to the date of
conﬁrmed PD or death, whichever occurred ﬁrst. ORR
was deﬁned as the percentage of patients with a com-
plete response (CR) or partial response (PR) according
to RECIST version 1.1, and DOR was deﬁned as the time
from when the criteria for CR or PR were ﬁrst met to the
occurrence of a PFS event.
Identiﬁcation of ALK Fusion Variant
ALK fusion variants were detected by a hybrid-
capture NGS test method using proprietary computa-
tional algorithms that enabled variant cells to be
accurately detected by discriminating sequencing arti-
facts from real mutations.10 Plasma samples were
analyzed by using the FoundationACT® platform and
tissue samples were analyzed using FoundationOne®
(Foundation Medicine, Cambridge, MA) (for details see
Supplementary Materials).10–12
Statistical Analysis
Comparison between treatment groupswith respect to
PFS was based on a stratiﬁed log-rank test at a 5% level of
signiﬁcance (two-sided). The Kaplan-Meier method was
used to estimate themedian PFS for each treatment group
with 95% CIs. The stratiﬁed Cox proportional hazards
regression model was used to estimate the treatment ef-
fect, expressed as an HR with a 95% CI, and ORR was
calculated by using the Clopper-Pearson method, with
treatment groups compared by using a stratiﬁed Mantel-
Haenszel test. Median DOR with 95% CIs was estimated
with the Kaplan-Meier method. PFS between the EML4-
ALK variant groups within each of the treatment arms
was compared by using a two-sided log-rank test at a 5%
signiﬁcance level. ORR between EML4-ALK variants was
compared by using the Pearson chi-square test.
Results
Patients
The overall patient population has been described
previously.3 Patients (the ITT population [N ¼ 303])
were randomized to receive treatment with alectinib
(n ¼ 152) or crizotinib (n ¼ 151). Of these, 122 patients
had IRC-assessed baseline CNS metastases (64 treated
with alectinib and 58 treated with crizotinib).3 In the
ITT population, baseline characteristics were generally
1236 Camidge et al Journal of Thoracic Oncology Vol. 14 No. 7balanced between the treatment arms. In patients with
CNS metastases at baseline, the number who received
whole-brain radiotherapy (17 treated with alectinib and
16 treated with crizotinib) or stereotactic radiosurgery
(six treated with alectinib and four treated with crizo-
tinib) was balanced, as was the number of baseline le-
sions (a median of two per arm).13
Of the 303 patients in the ITT population, 222 (73%)
were included in the plasma BEP subgroup (107 treated
with alectinib and 115 treated with crizotinib) and 203
(67%) were included in the tissue BEP subgroup (107
treated with alectinib and 96 treated with crizotinib).
Samples were not available for some patients because of
a lack of tumor tissue and/or circulating tumor DNA
yield or failure to pass NGS quality control. No ALK fu-
sions were detected in the plasma samples of 77 patients
or in the tissue samples of 67 patients. Non-EML4-ALK
fusions were detected in both plasma samples (n ¼ 10
[three from patients treated with alectinib and seven
from patients treated with crizotinib]) and tissue sam-
ples (n ¼ 12 [seven from patients treated with alectinib
and ﬁve from patients treated with crizotinib]), whereas
eight and 12 EML4-ALK variants other than variants 1, 2,
and 3a/b were found in plasma and tissue samples,
respectively. Baseline characteristics were generally
comparable for EML4-ALK variants 1, 2, and 3a/b; this
was also the case between treatment arms in both the
plasma and tissue subgroups (Supplementary Table 1).
The median durations of follow-up were 27.8 months
(range 0.5–38.7) with alectinib and 22.8 months (range
0.3–36.7) with crizotinib versus 18.6 months (range 0.5–
29.0) and 17.6 months (range 0.3–27.0), respectively, in
the primary analysis.3 In all, 80 patients (52.6%) had
discontinued alectinib and 123 (81.5%) had dis-
continued crizotinib (Supplementary Fig. 1).
Efﬁcacy (ITT Population)
PD or death occurred in 188 patients in the ITT
population (in 72 [47.4%] treated with alectinib and 116
[76.8%] treated with crizotinib). Investigator-assessed
PFS was prolonged with alectinib versus with crizoti-
nib in the ITT population (stratiﬁed HR ¼ 0.43, 95% CI:
0.32–0.58) (Fig. 1A); the median PFS times were 34.8
months (95% CI: 17.7–not estimable [NE]) and 10.9
months (95% CI: 9.1–12.9), respectively. The HR for
investigator-assessed PFS was less than 1.0 for all sub-
groups by baseline risk factor, with the exception of
active smokers (n ¼ 12) (Fig. 1B).
For alectinib versus for crizotinib, respectively, the
median PFS times in patients with baseline CNS metas-
tases were 27.7 months (95% CI: 9.2–NE) and 7.4
months (95% CI: 6.6–9.6) (HR ¼ 0.35, 95% CI: 0.22–
0.56), respectively, and for patients without baselineCNS metastases, the median PFS times were 34.8 months
(95% CI: 22.4–NE) and 14.7 months (95% CI: 10.8–20.3)
(HR ¼ 0.47, 95% CI: 0.32–0.71), respectively.
ORR was consistent with that reported in the primary
analysis; 82.9% for those treated with alectinib (95% CI:
75.95–88.51) versus 75.5% for those treated with crizoti-
nib (95% CI: 67.84–82.12) (Supplementary Table 2).
Overall, 119 of 152 alectinib-treated patients (78.3%) had
a PR compared with 111 of 151 crizotinib-treated patients
(73.5%) (Fig. 2). The median DOR was 33.1 months (95%
CI: 31.3–NE) with alectinib versus 11.1 months (95% CI:
7.5–13.0) with crizotinib (Supplementary Fig. 2).
In patients with CNS metastases at baseline, 49 of 64
alectinib-treated patients (76.6%) had a PR compared
with 38 of 58 crizotinib-treated patients (65.5%)
(Supplementary Fig. 3). In patients without baseline CNS
metastases, 70 of 88 alectinib-treated patients (79.5%)
and 73 of 93 crizotinib-treated patients (78.5%) ach-
ieved a PR.
In the patients who responded, depth of response
was more pronounced in those treated with alectinib:
tumor reductions greater than 75.0%, greater than 50%,
and greater than 25% occurred in 36.2%, 75.0%, and
82.9% of the alectinib-treated patients, respectively,
compared with 19.9%, 50.3%, and 82.8% of the
crizotinib-treated patients, respectively (Supplementary
Table 3).
As of December 1, 2017, a total of 91 patients had
died (43 of the 152 treated with alectinib [28.3%] and
48 of the 151 treated with crizotinib [31.8%]). The OS
data are immature (stratiﬁed HR ¼ 0.76, 95% CI: 0.50–
1.15) (Supplementary Fig. 4).
Prevalence of Rearrangements and Variants (BEP)
The percentages of ALK rearrangements, EML4-ALK
rearrangements, circulating nucleic acids, and ALK
single-nucleotide variants (SNVs) are shown in
Supplementary Figure 5. In total, three ALK SNVs of
unknown clinical signiﬁcance were detected in sepa-
rate patients in the plasma BEP subgroup, two of
which were found in EML4-ALK variant 1 (G1494R,
R1084C); no information on the ALK fusion was
available for the third. Overall, 13 ALK SNVs were
detected in the tissue BEP subgroup: three in EML4-
ALK variant 1 (G1018S, S737L, I248M), one in
variant 2 (V1039M), and two in variant 3a/b (R137G,
C1097Y) in the same patient, as well as seven ALK
SNVs that were detected in patients without detectable
ALK fusions (two of which mapped to the ALK kinase
domain [T1151M and N1353K]). There was no evi-
dence indicating the presence of any ALK inhibitor
resistance mutations that might inﬂuence the EML4-
ALK variant analysis.
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Figure 1. Efﬁcacy outcomes (intent-to-treat population): progression-free survival (PFS) (A) and PFS subgroup analysis (B).
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central nervous system; ECOG, Eastern Cooperative Oncology Group; IRC, independent review committee; NE, not estimable.
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fusion variant populations (variants 1, 2, and 3a/b)
was assessed for the plasma and tissue subgroups
(Table 1). EML4-ALK fusion variants 1 and 3a/b were the
most common, with similar prevalence across both the
plasma and tissue samples (EML4-ALK fusion variant 1,
37.0% and 42.7% in the plasma and tissue samples,
respectively; EML4-ALK fusion variant 3a/b, 36.3% and
37.1% in the plasma and tissue samples, respectively).EML4-ALK fusion variant 2 was less prevalent than
fusion variants 1 and 3a/b in both plasma and tissue
samples, but it was relatively more prevalent in plasma
samples than in tissue samples (16.3% versus 10.5%,
respectively). In the matched tumor (plasma and tissue)
samples (n ¼ 53) in which EML4-ALK fusions variants 1,
2, and 3a/b were detected, the same EML4-ALK variant
was detected in 79.2% of matched samples (n ¼ 42),
possibly owing to tumor heterogeneity.
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Figure 2. Investigator-assessed best overall response (intent-to-treat population): patients treated with alectinib (A) and
patients treated with crizotinib (B). CR, complete response; NE, not estimable; PD, progressive disease; PR, partial response.
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At the updated analysis cutoff (December 1, 2017),
the investigator-assessed PFS values for alectinib versus
for crizotinib resulted in comparable HRs between the
plasma (HR ¼ 0.32, 95% CI: 0.20–0.52, p < 0.0001) and
tissue BEP subgroups (HR ¼ 0.42, 95% CI: 0.25–0.70,
p ¼ 0.001); these were also comparable with the values
found for the ITT population (see the section Efﬁcacy
(ITT) and Supplementary Fig. 6).
The investigator-assessed median PFS time for each
of the EML4-ALK fusion variant populations was longer
for alectinib than for crizotinib based on both plasma
and tissue samples (Fig. 3A and B). In the plasma BEP
subgroup, the median PFS times in patients treated with
alectinib versus with crizotinib were 34.8 months versus
7.4 for variant 1; 24.8 months versus 8.8 months for
variant 2; and 17.7 months versus 9.1 months for variant
3a/b. In the tissue BEP subgroup, the median PFS times
in patients treated with alectinib versus those treatedTable 1. EML4-ALK Fusion Variant and ALK SNV Prevalence in
Variant
Plasma BEP
Combined
(n ¼ 222)
Crizotinib
(n ¼ 115)
EML4-ALK variant 1, n (%) 50 (37.0) 28 (41.2)
No SNV, n 48
SNV, n 2
EML4-ALK variant 2, n (%) 22 (16.3) 12 (17.6)
No SNV, n 22
SNV, n 0
EML4-ALK variant 3, n (%) 49 (36.3) 24 (35.3)
No SNV, n 49
SNV, n 0
EML4-ALK other, n (%) 8 (5.9) 2 (2.9)
Missing, n (%) 6 (4.4) 2 (2.9)
Total, n (%) 135 (100) 68 (100)
ALK, anaplastic lymphoma kinase gene; BEP, biomarker-evaluable populati
single-nucleotide variant.with crizotinib were NE versus 12.9 months for variant
1; 11.5 months versus 8.8 months for variant 2; and 34.9
months versus 14.6 months for variant 3a/b. The dif-
ferences in PFS between variants 1, 2, and 3a/b were not
signiﬁcant in any treatment arm or sample type (for
plasma from those treated with alectinib, p ¼ 0.4226; for
tissue from those treated with alectinib, p ¼ 0.1114; for
plasma from those treated with crizotinib, p ¼ 0.8504;
and for tissue from those treated with crizotinib,
p ¼ 0.9623).
ORR (BEP)
There was no signiﬁcant difference in the
investigator-assessed ORR between the EML4-ALK fusion
variant populations based on either plasma or tissue
samples from patients treated with alectinib or crizotinib
(Fig. 4A and B). When plasma samples were used, the
investigator-assessed ORR for patients with EML4-ALK
fusion variants 1, 2, and 3a/b was higher for thoseBoth the Tissue Sample and Plasma BEP Subgroups
Tissue BEP
Alectinib
(n ¼ 107)
Combined
(n ¼ 203)
Crizotinib
(n ¼ 96)
Alectinib
(n ¼ 107)
22 (32.8) 53 (42.7) 28 (43.7) 25 (41.7)
50
3
10 (14.9) 13 (10.5) 5 (7.8) 8 (13.3)
12
1
25 (37.3) 46 (37.1) 25 (39.1) 21 (35.0)
45
1
6 (9.0) 12 (9.7) 6 (9.4) 6 (10.0)
4 (6.0) 0 (0.0) 0 (0.0) 0 (0.0)
67 (100) 124 (100) 64 (100) 60 (100)
on; EML4, echinoderm microtubule-associated protein-like 4 gene; SNV,
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Figure 3. Progression-free survival (PFS) (investigator [INV]) by echinoderm microtubule-associated protein-like 4 gene
(EML4)-anaplastic lymphoma kinase gene (ALK) fusion variant in both the tissue and plasma biomarker-evaluable population
subgroups.
July 2019 Alectinib in NSCLC: Updated ALEX Study Data 1239treated with alectinib than that for those treated with
crizotinib. When tissue samples were used, the
investigator-assessed ORR was higher with alectinib
than with crizotinib for patients with variant 1, similar
for patients with variant 3a/b, and lower for patients
with variant 2 (62.5% for those treated with alectinib
versus 100% for those treated with crizotinib [see
Fig. 4B]). However, the numbers of patients with variant
2 were too low to draw meaningful conclusions (n ¼ 8
and n ¼ 5, respectively).DOR (BEP)
The median investigator-assessed objective DOR in
patients treated with alectinib was comparable for
all three EML4-ALK fusion variant populations
according to both plasma and tissue samples
(Supplementary Fig. 7). When plasma samples were
used, the median investigator-assessed objective DOR for
patients treated with crizotinib was comparable forEML4-ALK fusion variant populations 1 and 2, but longer
for variant population 3a/b (see Supplementary Fig. 7).
When tissue samples were used, the median
investigator-assessed objective DOR for patients treated
with crizotinib was comparable for EML4-ALK fusion
variant populations 1 and 3a/b. Patients with EML4-ALK
fusion variant 2 had a shorter median DOR; however, the
patient numbers were low (n ¼ 5 [see Supplementary
Fig. 7]). The median investigator-assessed DOR was
longer with alectinib than with crizotinib in all three
EML4-ALK fusion variant populations using both plasma
and tissue samples.Safety (Safety Population)
The median treatment durations (as of December 1,
2017) were 27.0 months (range 0.0–39.0) with alectinib
and 10.8 months (range 0.0–37.0) with crizotinib
versus 17.9 months (range 0.0–29.0) and 10.7 months
(range 0.0–27.0), respectively, in the primary analysis.3
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Figure 4. Objective response rate (ORR) (investigator [INV]-conﬁrmed) by echinoderm microtubule-associated protein-like 4
gene (EML4)–anaplastic lymphoma kinase gene (ALK) fusion variant in both the tissue and plasma biomarker-evaluable
population subgroups. *Pearson’s chi-square test comparing all three variants. CR, complete response; PD, progressive dis-
ease; PR, partial response; V, variant.
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treatments.
Despite the longer treatment duration, fewer patients
had grade 3 to 5 AEs with alectinib (44.7%) than with
crizotinib (51.0% [Table 2 and Supplementary Table 4]).
Fewer alectinib-treated patients had fatal AEs
(3.9%) than did the crizotinib-treated patients (4.6%)
(Supplementary Table 5). Compared with the crizotinib-
treated patients, fewer alectinib-treated patients had AEs
leading to dose reduction (16.4% with alectinib versus
20.5% with crizotinib) or interruption (22.4% with
alectinib versus 25.2% with crizotinib).
In the case of AEs for which the rate differed by 5%
between treatment arms, most occurred at a higher
frequency with crizotinib than with alectinib (Table 2).
With regard to AEs that occurred with an incidence rate of
10% in either treatment arm, the most common was
constipation (35.5% with alectinib versus 33.8% with
crizotinib) (Supplementary Table 6).
The most frequently reported AEs considered to be
related to study treatment (any grade, incidence of
30% in any arm) were nausea (7.9% with alectinib
versus 43.0% with crizotinib), increased alanine trans-
aminase level (14.5% with alectinib versus 30.5% with
crizotinib), and diarrhea (6% with alectinib versus 38%
with crizotinib). AEs related to study treatment occur-
ring in 5% of patients in either treatment arm are
listed in Supplementary Table 7.
The proportion of patients with AEs leading to
treatment discontinuation was 13.2% with both alectiniband crizotinib; the most common of these AEs (incidence
3% in any arm) were increased alanine transaminase
level (1.3% with alectinib versus 6.0% with crizotinib),
increased aspartate transaminase level (1.3% with
alectinib versus 4.0% with crizotinib), and pneumonitis
(0.7% with alectinib versus 3.3% with crizotinib)
(Supplementary Table 8).
Discussion
In this updated exploratory analysis, with approxi-
mately 10 more months of follow-up than in the primary
analysis, the superior efﬁcacy of alectinib versus that of
crizotinib was conﬁrmed. The median follow-up was
longer with alectinib (27.8 months) than with crizotinib
(22.8 months). In the ITT population, alectinib reduced
the risk of PD or death by 57% (stratiﬁed HR ¼ 0.43,
95% CI: 0.32–0.58 [previous data cutoff HR ¼ 0.47]).
The investigator-assessed median PFS was longer with
alectinib (34.8 months [previous data cutoff NE]) than
with crizotinib (10.9 months). The data for the crizotinib
arm remain comparable with that of the primary anal-
ysis3 and with that reported in the PROFILE 1014 trial of
ﬁrst-line crizotinib versus chemotherapy (median PFS
for crizotinib 10.9 months), whereas the longer follow-
up shows improved efﬁcacy in terms of prolonged me-
dian PFS and DOR in the alectinib arm than in the prior
analysis.14
Although caution must be used when comparing
results across trials, the median PFS achieved with alec-
tinib in the ﬁrst-line setting in the current analysis is
Table 2. Safety Overview and AEs of Any Grade That
Differed by 5% in Frequency between Treatment Arms
(Safety Population)
AE, n (%)
Crizotinib
(n ¼ 151)
Alectinib
(n ¼ 152)
All-grade AEs 147 (97.4) 147 (96.7)
Serious AEs 46 (30.5) 46 (30.3)
Grade 3–5 AEs 77 (51.0) 68 (44.7)
Fatal AEs 7 (4.6) 6 (3.9)
AEs leading to treatment
discontinuation
20 (13.2) 20 (13.2)
AEs leading to dose reduction 31 (20.5) 25 (16.4)
AEs leading to dose interruption 38 (25.2) 34 (22.4)
Total patients with any grade AEs
with 5% difference in frequency
between arms
135 (89.4) 115 (75.7)
Anemia 11 (7.3) 34 (22.4)
Blood bilirubin level increased 2 (1.3) 29 (19.1)
Peripheral edema 48 (31.8) 28 (18.4)
ALT level increased 50 (33.1) 26 (17.1)
AST level increased 40 (26.5) 24 (15.8)
Myalgia 3 (2.0) 25 (16.4)
Nausea 75 (49.7) 24 (15.8)
Diarrhea 70 (46.4) 20 (13.2)
Insomnia 9 (6.0) 18 (11.8)
Vomiting 62 (41.1) 14 (9.2)
Weight increased 0 14 (9.2)
Dizziness 23 (15.2) 13 (8.6)
Musculoskeletal pain 4 (2.6) 12 (7.9)
Photosensitivity reaction 0 9 (5.9)
Neutropenia 12 (7.9) 4 (2.6)
Dysgeusia 30 (19.9) 5 (3.3)
Dyspepsia 14 (9.3) 5 (3.3)
Visual impairment 18 (11.9) 3 (2.0)
Vision blurred 11 (7.3) 3 (2.0)
Alopecia 12 (7.9) 1 (0.7)
g-Glutamyltransferase level
increased
11 (7.3) 1 (0.7)
Photopsia 10 (6.6) 0
ECG QT prolonged 8 (5.3) 0
AE, adverse event; ALT, alanine transaminase; AST, aspartate transaminase;
ECG, electrocardiogram.
July 2019 Alectinib in NSCLC: Updated ALEX Study Data 1241numerically greater than that reported with sequential
ﬁrst-line crizotinib (10.9 months)14 followed by second-
line ceritinib (7.2 months) or alectinib (8.3 months).15
These data highlight the beneﬁt of alectinib as a ﬁrst-line
treatment for ALK-positive NSCLC as reﬂected in Na-
tional Comprehensive Cancer Network guidelines, which
recommend alectinib as the preferred ﬁrst-line treatment
in this indication,16 and the European Society for Medical
Oncology guidelines, which recognize alectinib as a better
ﬁrst-line treatment option than crizotinib.17
In this updated analysis, the ORR in the ITT popu-
lation remained the same as in the primary analysis
(82.9% with alectinib versus 75.5% with crizotinib). To
gain a better understanding of response quality, we
assessed tumor reductions beyond the RECIST criteria.Compared with the crizotinib arm, the alectinib arm
included more patients who had tumor reductions
greater than 50% or greater than 75%. This improve-
ment was seen in patients with and without baseline
CNS metastases. In keeping with the greater depth of
response in the alectinib arm, PFS curves began to
show a clear separation between treatment arms at
6 months.
Although the numbers per EML4-ALK variant are
relatively small (particularly for variant 2), this study
represents the largest analysis of ALK inhibitor efﬁcacy
by ALK fusion variant type in the context of a prospective
phase III randomized clinical trial. Data on the associa-
tion between variant type and treatment outcomes are
important but limited, as commonly used methods to
detect ALK-positive NSCLC (e.g., immunohistochemistry
or ﬂuorescence in situ hybridization) do not provide
information on the speciﬁc ALK variant. The prevalences
of EML4-ALK variants in the ALEX study are consistent
with those in previous reports.5,8
Efﬁcacy analyzed by the presence of speciﬁc EML4-ALK
fusion variants in tissue and plasma samples was similar to
that in the ITT population and demonstrates that the efﬁ-
cacy beneﬁt of alectinib versus crizotinib in the phase III
ALEX trial is observed across all EML4-ALK fusion variants.
A possible exception was in the efﬁcacy assessments of
patients with variant 2 in tissue samples, which were likely
affected by the low sample numbers (eight from those
treated with alectinib and ﬁve from those treated with
crizotinib). It was also of note that the median PFS and
DOR were generally shorter in the analysis of EML4-ALK
variants than in the ITT population, which may also be
related to the lower numbers of patients with valid
samples.
A study led by Lin et al. in 2018 showed that tumors
with the EML4-ALK variant 3a/b are more prone to
development of resistance mutations (ALK G1202R in
particular) and that there is a trend toward lower median
PFS in patients with variant 3a/b versus those with
variant 1, when treated with second-generation ALK in-
hibitors after crizotinib.8 That study also reported a
signiﬁcantly longer PFS in patients with variant 3 than in
patients with variant 1, who were treated with the third-
generation ALK inhibitor lorlatinib after crizotinib and at
least one second-generation inhibitor.8 However, the cur-
rent analysis using prospective phase III data suggests that
there is a similar level of beneﬁt (in terms of PFS, ORR, and
DOR) from treatment with alectinib and crizotinib in pa-
tients with variants 1 and 3a/b in the ﬁrst-line setting.
Furthermore, there was no evidence for the presence of
any baseline ALK resistance mutations in patients from the
ALEX trial that may have biased efﬁcacy outcomes in
response to either alectinib or crizotinib treatment.
Future retrospective analyses will likely provide further
1242 Camidge et al Journal of Thoracic Oncology Vol. 14 No. 7information on the association of the efﬁcacy of other ALK
inhibitors and ALK fusion variant type.
There were no new or unexpected safety ﬁndings
for alectinib. The safety proﬁle of alectinib compared
favorably with that of crizotinib, despite an increase in
median treatment duration of approximately 9 months
versus that in the primary analysis (27.0 months versus
17.9 months); the median treatment duration for crizoti-
nib remained approximately the same (10.8 months
versus 10.7 months in the primary analysis).
Limitations
Limitations of the updated analysis include the fact
that it was exploratory and that IRC assessments were
not collected after the cutoff date for the primary anal-
ysis. Further follow-up for OS is required, as the OS data
are not yet mature (a future survival analysis is planned;
patients are still receiving treatment). The EML4-ALK
fusion variant analysis is limited by the relatively small
patient numbers and by the fact that it was exploratory.
In addition, only the three most common EML4-ALK
fusion variants were compared; the impact of other vari-
ants (including non–EML4-ALK) is unknown. Although
further assessment of postprogression samples may pro-
vide insight into how ALK fusion variants can affect
mechanisms of resistance to ALK- inhibitor treatment, data
are not yet available to assess this or the potential of ALK
fusion variant type on OS.
Conclusion
With longer follow-up, the superior beneﬁt of alecti-
nib versus crizotinib in investigator-assessed PFS in
untreated ALK-positive NSCLC is greater than in the
initial analyses. PFS, ORR, and DOR were unaffected by
baseline EML4-ALK variant, and alectinib remained su-
perior to crizotinib across variant subtypes. Alectinib
was better tolerated than crizotinib despite longer
treatment duration.
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